Wealth Enhancement Advisory Services
ADCT icon

Wealth Enhancement Advisory Services’s ADC Therapeutics ADCT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.1K Sell
16,439
-2,904
-15% -$3.4K ﹤0.01% 4098
2026
Q2 		$25K Buy
19,343
+5,113
+36% +$14.9K ﹤0.01% 4010
2026
Q1 		$53.8K Buy
14,230
+2,508
+21% +$9.9K ﹤0.01% 3420
2025
Q4 		$41.5K Buy
11,722
+125
+1% +$507 ﹤0.01% 3538
2025
Q3 		$50K Buy
11,597
+365
+3% +$1.15K ﹤0.01% 3429
2025
Q2 		$32K Sell
11,232
-3,758
-25% -$7.9K ﹤0.01% 3263
2025
Q1 		$21.1K Buy
+14,990
New +$25.5K ﹤0.01% 2913

Other funds holding ADCT

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's ADCT Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its ADC Therapeutics (ADCT) stake by 15% in Q3 2026, selling an estimated $3.4K and leaving 16,439 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4098.

Wealth Enhancement Advisory Services first reported a position in ADCT in Q1 2025 and has held it in 7 quarters since. The position peaked at $53.8K in Q1 2026. 75 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Wealth Enhancement Advisory Services held 16,439 shares of ADC Therapeutics worth $26.1K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 2,904 ADC Therapeutics shares in Q3 2026, an estimated $3.4K.
  • ADC Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4098 holding.
  • Wealth Enhancement Advisory Services first reported a position in ADC Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Wealth Enhancement Advisory Services's ADC Therapeutics position peaked at $53.8K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.